Pharmaceutical composition, topical preparation, and preparation method therefor and use thereof
By optimizing the mass ratio of diethylene glycol monoethyl ether and polyethylene glycol 400 in the drug composition, an anhydrous system was formed, which solved the problems of insufficient skin retention and permeability of topical preparations, achieving rapid drug penetration and retention on the skin and reducing the risk of systemic side effects.
Patent Information
- Application Number
- PCT/CN2023/096089
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Existing topical formulations have insufficient skin retention and permeability, making it difficult for the drug to effectively penetrate the stratum corneum and posing a risk of systemic side effects.
The pharmaceutical composition comprises the active pharmaceutical ingredient, diethylene glycol monoethyl ether, and polyethylene glycol 400. By optimizing their mass ratio, an anhydrous system is formed, which promotes rapid drug penetration and retention in the skin, avoiding systemic side effects.
The pharmaceutical composition exhibits good permeability and retention on the skin, increasing local drug concentration, reducing the risk of systemic side effects, and is stable without crystallization.
Smart Images

Figure CN2023096089_28112024_PF_FP_ABST
Abstract
Description
A pharmaceutical composition, an external preparation, and its preparation method and application Technical Field
[0001] The present invention relates to a pharmaceutical composition, an external preparation, and a preparation method and application thereof. Background Art
[0002] Cytokines in skin immune diseases activate JAKs (January Activation Kinases) in various cells through their respective receptors, regulating the differentiation and proliferation of related immune cells and inhibiting cytokine secretion. The JAK / STAT pathway can inhibit immune cell activation and T cell-mediated inflammation, making it a popular target for inflammatory diseases. JAKs are a family of cytoplasmic protein tyrosine kinases that include JAK1, JAK2, JAK3, and TYK2.
[0003] Currently, several JAK inhibitors are used to treat skin lesions, including oral formulations such as tofacitinib, deucravacitinib, baricitinib, and ruxolitinib. The Phase III clinical trial for oral tofacitinib has been suspended due to the FDA's request for further safety data. Systemic administration of the drug may cause serious adverse reactions. Topical administration of the active pharmaceutical ingredient has become the preferred method for treating skin diseases such as rheumatoid arthritis, psoriasis, and alopecia areata.
[0004] However, the skin retention and permeability of current topical preparations containing active pharmaceutical ingredients need to be improved during application.
[0005] Summary of the Invention
[0006] The technical problem to be solved by the present invention is to overcome the shortcomings of existing topical preparations, such as low skin retention and poor permeability, and to provide a pharmaceutical composition, topical preparation, and preparation method and application thereof. The topical preparation prepared from the pharmaceutical composition provided by the present invention has stable properties, does not crystallize, has a good skin feel, can promote rapid drug penetration through the stratum corneum, has good epidermal and dermal retention, and can deliver drugs to the skin in a targeted manner, thereby reducing systemic side effects and achieving higher local concentrations. It has a strong therapeutic effect, stability, and can reduce safety risks.
[0007] The present invention solves the above technical problems through the following technical solutions.
[0008] The present invention provides a pharmaceutical composition, which comprises a pharmaceutical active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400 (PEG400); the pharmaceutical composition does not contain water;
[0009] Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the active pharmaceutical ingredient has the structural formula (I):
[0010] In the present invention, the pharmaceutical active ingredient having structural formula (I) can be prepared by the preparation method disclosed in Example 113 of CN113227074A.
[0011] In the present invention, the dosage of the pharmaceutical active ingredient may be 0.001-10%, for example 0.1%, 0.3%, 0.6%, 1.0%, 1.2%, 1.5% or 2.0%, where % refers to the mass percentage of the pharmaceutical active ingredient in the pharmaceutical composition.
[0012] In the present invention, diethylene glycol monoethyl ether not only has the function of increasing or accelerating the penetration of drugs through the skin, but also has the function of serving as a solvent to dissolve compounds.
[0013] In the present invention, the amount of diethylene glycol monoethyl ether can be 15-40%, for example, 20.0%, 23.0% or 33.8%, where % refers to the mass percentage of diethylene glycol monoethyl ether in the pharmaceutical composition.
[0014] In the present invention, the mass ratio of the pharmaceutical active ingredient to the diethylene glycol monoethyl ether is preferably 1:(10.0-250.0), for example, 1:13.33, 1:15.33, 1:16.67, 1:16.90, 1:20, 1:23, 1:33.33, 1:66.67, 1:76.67, 1:200 or 1:230.
[0015] In the present invention, the amount of polyethylene glycol 400 can be 30-55%, for example, 30.4%, 38.8%, 45.3%, 52.5% or 52.9%, where % refers to the mass percentage of polyethylene glycol 400 in the pharmaceutical composition.
[0016] In the present invention, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is preferably 1:(0.5-3.0), for example, 1:0.90, 1:1.94, 1:1.97, 1:2.63 or 2.65.
[0017] In the present invention, preferably, the pharmaceutical composition further comprises polyethylene glycol 3350 (PEG3350).
[0018] Wherein, when the pharmaceutical composition includes polyethylene glycol 3350, the amount of polyethylene glycol 3350 can be 25.0-45.0%, for example, 25.8%, 26.3%, 26.5%, 27%, 27.2%, 30%, 30.5%, 31.2%, 31.4%, 33.8% or 40%.
[0019] Wherein, when the pharmaceutical composition includes polyethylene glycol 3350, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 can be 1:(0.5-3.6), preferably 1:(0.5-3.0), for example, 1:1.00, 1:1.29, 1:1.30, 1:1.32, 1:1.33, 1:1.35, 1:1.36, 1:1.37 or 1:2.00.
[0020] In the present invention, preferably, the pharmaceutical composition further comprises one or more of an antioxidant, a preservative, a hardener and a moisturizer.
[0021] The antioxidant may be an aromatic amine antioxidant, such as butylated hydroxytoluene.
[0022] The amount of the antioxidant may be 0.05-0.2%, for example 0.1%.
[0023] The preservative may be one or more of methylparaben, sorbic acid and salts thereof, such as methylparaben.
[0024] The amount of the preservative may be 0.05-0.2%, for example 0.1%.
[0025] The hardener may be one or more of paraffin, beeswax, cetostearyl alcohol, white petrolatum and glyceryl mono- and distearate.
[0026] The amount of the hardener may be 5-40%, for example, 9.8%, 22.1%, 30.65% or 37.6%.
[0027] The moisturizing agent may be one or more of glycerin, light liquid paraffin, soybean oil, medium chain triglycerides, sodium hyaluronate, urea, propylene glycol, butylene glycol, panthenol, sodium pyrrolidone carboxylate and trehalose, preferably propylene glycol.
[0028] The amount of the moisturizer can be 2-80%, such as 5.0%, 9.0%, 20.0%, 37.5% or 77.5%.
[0029] In the present invention, the pharmaceutical composition may be in the form of a solution, gel, ointment or cream.
[0030] In the present invention, when the pharmaceutical composition is a semisolid, such as a cream, the particle size of the active pharmaceutical ingredient may be less than 180 μm.
[0031] In the present invention, after the components in the pharmaceutical composition are mixed, no crystallization phenomenon occurs, and a single-phase system is formed.
[0032] In some preferred embodiments, the pharmaceutical composition comprises the above-mentioned active pharmaceutical ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not contain water;
[0033] The mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6).
[0034] In some preferred embodiments, the pharmaceutical composition comprises the above-mentioned active pharmaceutical ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not contain water;
[0035] Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.0).
[0036] In some preferred embodiments, the pharmaceutical composition comprises, by weight percentage:
[0037] In some preferred embodiments, the pharmaceutical composition comprises, by weight percentage:
[0038] The present invention also provides an external preparation comprising the above-mentioned pharmaceutical composition.
[0039] In the present invention, the external preparation can be a liquid preparation or a semisolid preparation.
[0040] Wherein, the liquid preparation can be a liniment or a tincture.
[0041] Wherein, the semisolid preparation can be a cream, an organogel, an ointment or a paste.
[0042] In some preferred embodiments, the ointment comprises, by weight percentage:
[0043] Preferably, the ointment comprises, by weight percentage:
[0044] More preferably, the ointment comprises, by weight percentage:
[0045] Preferably, the ointment comprises, by weight percentage:
[0046] More preferably, the ointment comprises, by weight percentage:
[0047] More preferably, the ointment comprises, by weight percentage:
[0048] Preferably, the ointment comprises, by weight percentage:
[0049] More preferably, the ointment comprises, by weight percentage:
[0050] Preferably, the pharmaceutical composition comprises, by weight percentage:
[0051] The present invention also provides a method for preparing the above-mentioned pharmaceutical composition, which comprises the following steps:
[0052] (1) Preparation of API solution: Mix the active pharmaceutical ingredient, diethylene glycol monoethyl ether, and polyethylene glycol 400 at 50-80°C until dissolved;
[0053] (2) Prepare the matrix solution: Heat polyethylene glycol 3350 at 50-80°C until it melts;
[0054] (3) Preparation of ointment: Mix the API solution and the base solution under stirring conditions.
[0055] In step (1), the mixing temperature is preferably 50°C or 80°C.
[0056] In step (2), preferably, the raw materials further include one or more of an antioxidant, a preservative, a hardener and a moisturizer.
[0057] In step (2), preferably, the raw material further comprises diethylene glycol monoethyl ether.
[0058] Among them, preferably, when the raw material in step (2) includes diethylene glycol monoethyl ether, the amount of diethylene glycol monoethyl ether in step (1) is 2 / 3 of the prescribed amount, and the amount of diethylene glycol monoethyl ether in step (2) is 1 / 3 of the prescribed amount.
[0059] In a preferred embodiment, the preparation of the matrix solution comprises the following steps: adding methylparaben to diethylene glycol monoethyl ether, stirring at 50-80° C. until completely dissolved; then adding butylated hydroxytoluene and polyethylene glycol 3350, stirring until melted.
[0060] In step (2), the heating temperature is preferably 50°C or 80°C.
[0061] In step (3), the stirring speed can be conventional in the art, preferably 315 rpm.
[0062] In step (3), the stirring time can be conventional in the art, preferably 10-15 minutes.
[0063] In step (3), the mixing temperature is preferably 50-60°C.
[0064] In step (3), after the mixing is completed, a cooling operation may also be included.
[0065] The cooling may be carried out by circulating water.
[0066] The present invention also provides a use of the above-mentioned pharmaceutical composition or external preparation in preparing a drug for treating autoimmune diseases.
[0067] In the present invention, the autoimmune disease can be arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
[0068] The present invention also provides a method for treating an autoimmune disease, comprising administering a therapeutically effective amount of the above-mentioned pharmaceutical composition or external preparation to a subject.
[0069] In the present invention, the autoimmune disease can be arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
[0070] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0071] In the present invention, except for the active pharmaceutical ingredients, all the reagents and raw materials used are commercially available.
[0072] The positive progress effect of the present invention is:
[0073] The topical preparation prepared from the pharmaceutical composition provided by the present invention has stable properties, does not crystallize, has a good skin feel, can promote the rapid penetration of drugs into the stratum corneum, and has good epidermal and dermal retention capacity, and can deliver drugs in a targeted manner to the skin, thereby reducing systemic side effects and achieving higher local concentrations. It has a strong therapeutic effect, stability, and can reduce safety risks. BRIEF DESCRIPTION OF THE DRAWINGS
[0074] Figure 1 shows the microscopic observation results of the ointment prepared by 3A in Example 3. Part (a) of Figure 1 shows the initial conditions, and part (b) of Figure 1 shows the accelerated conditions after 6 months.
[0075] FIG2 is the microscopic observation result of the cream prepared in Example 7 under the initial conditions.
[0076] FIG3 is the microscopic observation result of the hydrogel prepared in Example 10 under the initial conditions.
[0077] Figure 4 shows the microscopic observation results of the organogel prepared in Example 12 under initial conditions. Part (a) of Figure 4 shows the initial conditions, and part (b) of Figure 4 shows the accelerated conditions after 6 months.
[0078] FIG5 is the microscopic observation result of the liniment prepared in Example 13.
[0079] FIG6 is a graph showing the square root of the cumulative drug release per unit area versus time in Effect Example 2.
[0080] FIG7 is a release rate-specification curve diagram in Effect Example 2. DETAILED DESCRIPTION
[0081] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0082] In a specific embodiment of the present invention, the pharmaceutical active ingredient having structural formula (I) is prepared by the preparation method disclosed in Example 113 of CN113227074A.
[0083] Example 1 Ointment
[0084] The ointment prescription is shown in Table 1 below.
[0085] Table 1
[0086] The preparation process is as follows:
[0087] (1) Preparation of API solution: Weigh the prescribed amount of active ingredient, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0088] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0089] (3) Preparation of ointment: Slowly add the melted matrix solution to the API solution while stirring. Stir for 10 min at a stirring speed of 315 rpm and cool to form an ointment.
[0090] Example 2 Ointment
[0091] The ointment prescription is shown in Table 2 below.
[0092] Table 2
[0093] The preparation process is as follows:
[0094] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient API, diethylene glycol monoethyl ether (Transcutol P), and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until the API is completely dissolved.
[0095] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0096] (3) Preparation of ointment: Slowly add the melted matrix solution to the API solution while stirring. After addition, stir and cool to 35°C at a stirring speed of 310 rpm, and finally let it stand and cool to room temperature.
[0097] Example 3 Ointment
[0098] The ointment prescription is shown in Table 3 below.
[0099] Table 3
[0100] The preparation process is as follows:
[0101] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and 2 / 3 of the prescribed amount of polyethylene glycol 400 (PEG 400) into a container, heat at 50°C-60°C, and stir until completely dissolved.
[0102] (2) Prepare the matrix solution: Weigh the prescribed amount of methylparaben and add it to 1 / 3 of the prescribed amount of PEG400. Stir at 70±5°C until the methylparaben is completely dissolved. Then add the prescribed amount of polyethylene glycol 3350 (PEG 3350) and butylated hydroxytoluene (BHT). Stir at 70±5°C until the PEG3350 and BHT are completely melted. Cool to 50-60°C.
[0103] (3) Preparation of ointment: Pour the API solution into the matrix solution while stirring at 50-60°C. After stirring for 15 minutes, add tartrazine to adjust the color and cool the solution to room temperature with stirring.
[0104] Take a clean glass slide, take an appropriate amount of sample 3A (about 0.01 g each time), apply it on the slide, cover it with a coverslip, and gently press the coverslip. First, observe the ointment under a microscope under the conditions of eyepiece 10X, objective lens 40X, and polarization 300° (initial conditions and accelerated conditions of 40°C and 75% RH for 6 months). The results are shown in part (a) of Figure 1 and part (b) of Figure 1, indicating that the ointment has no crystallization phenomenon.
[0105] Example 4 Ointment
[0106] The ointment prescription is shown in Table 4 below.
[0107] Table 4
[0108] The preparation process is as follows:
[0109] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0110] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), hardener, butylated hydroxytoluene, methylparaben and propylene glycol and heat them in a water bath at 80°C and stir until melted.
[0111] (3) Preparation of ointment: Slowly add the melted matrix solution to the API solution while stirring. Stir for 10 min at a stirring speed of 315 rpm, and finally let it stand and cool to room temperature.
[0112] Example 5 Ointment
[0113] The ointment prescription is shown in Table 5 below.
[0114] Table 5
[0115] The preparation process is as follows:
[0116] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0117] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0118] (3) Preparation of ointment: Slowly add the melted matrix solution to the API solution while stirring. Stir for 10 min at a stirring speed of 315 rpm, and finally let it stand and cool to room temperature.
[0119] Example 6 Ointment
[0120] The ointment prescription is shown in Table 6 below.
[0121] Table 6
[0122] The preparation process is as follows:
[0123] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P), polyethylene glycol 600 (PEG 600) and moisturizer into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0124] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0125] (3) Preparation of ointment: Slowly add the melted matrix solution to the API solution while stirring. Stir for 10 min at a stirring speed of 315 rpm and cool to form an ointment.
[0126] Example 7 Cream
[0127] The cream prescription is shown in Table 7 below.
[0128] Table 7
[0129] The preparation process is as follows:
[0130] (1) Preparation of API solution: Add the prescribed amount of the active ingredient API to diethylene glycol monoethyl ether (Transcutol P), heat to 80°C to dissolve the API, then add the prescribed amount of propylene glycol and stir for 3 minutes to mix evenly.
[0131] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7 stearate, oleoyl polyoxyethylene glyceride, mono- and distearic glyceride, and medium-chain triglyceride, and heat at 80°C until melted.
[0132] (3) Preparation of cream: Add the API solution to the prepared oil phase under stirring, start homogenization (speed 15000 rpm), slowly add the oil phase containing the API into 80℃ purified water, and homogenize for 10 min.
[0133] The prepared cream had a uniform texture. Sample 7A was observed under the initial conditions according to the method in Example 3, and the results are shown in Figure 2. It shows that the emulsion droplets in the cream are uniform, with a particle size of about 10-30 μm.
[0134] Example 8 Cream
[0135] The cream prescription is shown in Table 8 below.
[0136] Table 8
[0137] The preparation process is as follows:
[0138] (1) Preparation of API solution: Dissolve the prescribed amount of the active ingredient in a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) at 80°C.
[0139] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7-stearate, oleoyl polyoxyethylene glyceride, mono- and distearic glyceride, and medium-chain triglyceride, and heat at 80°C until melted.
[0140] (3) Preparation of aqueous phase:
[0141] Hydroxypropyl methylcellulose solution (8A, 8B, 8C): Weigh the prescribed amount of purified water and slowly add the hydropropyl methylcellulose while stirring. Stir until the hydropropyl methylcellulose is completely dissolved.
[0142] Carbomer solution (8D): Dissolve the prescribed amount of carbomer in purified water.
[0143] (4) Preparation of cream:
[0144] a. Preparation of cream (Batch 8A / Batch 8B): Mix the oil phase and API solution in an 80°C water bath with magnetic stirring for 5 minutes. When the temperature drops to 50°C, add the aqueous phase (hydroxypropyl methylcellulose solution). Stir vigorously for 5 minutes (at 520 rpm) and allow to cool.
[0145] b. Preparation of cream (Batch 8C): Mix the oil phase and API solution in an 80°C water bath with magnetic stirring for 10 minutes. When the temperature drops to 50°C, add the aqueous phase (hydroxypropyl methylcellulose solution) and homogenize at a speed of 9.0 ± 0.2 kr / min for 5 minutes. Then, continue homogenizing until the temperature drops to 30°C (at a speed of 8.8 kr / min).
[0146] c. Preparation of cream (8D batch): The oil phase and API solution were mixed with magnetic stirring in an 80°C water bath for 10 min, added to the aqueous phase (carbomer solution), stirred vigorously for 5 min (360 rpm), and cooled to 30°C with stirring (200 rpm).
[0147] Example 9 cream
[0148] The cream prescription is shown in Table 9 below.
[0149] Table 9
[0150] The preparation process is as follows:
[0151] (1) Preparation of API solution: Dissolve the prescribed amount of the active ingredient in a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400).
[0152] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7-stearate, hexadecanol (9A), monoacylglycerol (9B), mono- and distearic glycerol (9C), light liquid paraffin, and medium-chain triglycerides, and heat them in a water bath at 80°C to melt into a liquid mixture.
[0153] (3) Prepare the aqueous phase: Dissolve the prescribed amount of Tween 80 and ethylparaben in purified water at 70°C.
[0154] (4) Preparation of cream: Mix the oil phase and API solution in a 70°C water bath with magnetic stirring for 5 min. Add the aqueous phase at 70°C, shear at high speed for 5 min, and then take an appropriate amount and place it in an EP tube and let it cool.
[0155] Example 10 Hydrogel
[0156] The hydrogel formulation is shown in Table 10 below.
[0157] Table 10 Note: “qs” in the table means trace amount.
[0158] The preparation process is as follows:
[0159] (1) Preparation of API solution: Add a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) to the prescribed amount of the active ingredient API and stir at 80°C for 10 min to dissolve the API.
[0160] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely dissolve it in purified water.
[0161] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm), add a trace amount of 2M sodium hydroxide solution, continue stirring for 3 minutes after all the solution is added, make up the remaining water in the prescription and stir for 5 minutes (stirring speed 900 rpm).
[0162] Sample 10A was microscopically observed under the initial conditions using the method described in Example 3. The results are shown in Figure 3. It shows that the hydrogel had a small amount of crystallization under the initial conditions, with a crystal size of approximately 15 μm.
[0163] Example 11 Hydrogel
[0164] The hydrogel formulation is shown in Table 11 below.
[0165] Table 11
[0166] The preparation process is as follows:
[0167] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient, add diethylene glycol monoethyl ether (or dimethyl sulfoxide) and PEG 400, and stir at 50°C for 10 min to dissolve the API.
[0168] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely dissolve it in purified water.
[0169] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm). Continue stirring for 3 minutes after all the solution is added. Make up the remaining water in the formula and stir for 5 minutes (stirring speed 900 rpm).
[0170] Example 12 Organogel
[0171] The organogel formulation is shown in Table 12 below.
[0172] Table 12
[0173] The preparation process is as follows:
[0174] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance and diethylene glycol monoethyl ether (Transcutol P) and stir at 50°C for 20 min.
[0175] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely swell it with the prescribed amount of polyethylene glycol 400 or propylene glycol.
[0176] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm). After all the solution is added, continue stirring for 3 minutes (stirring speed 900 rpm).
[0177] Sample 12A (placed at initial and accelerated conditions of 40°C and 75% RH for 6 months) was microscopically observed using the method described in Example 3. The results, as shown in parts (a) and (b) of FIG. 4 , indicate that the organogel exhibited no crystallization.
[0178] Example 13 Liniment
[0179] The liniment prescription is shown in Table 13 below.
[0180] Table 13
[0181] The preparation process is as follows:
[0182] The prescribed amount of active pharmaceutical ingredient and permeation enhancer are weighed, the prescribed amount of permeation enhancer is mixed, and then the active pharmaceutical ingredient is added and stirred at 50±5° C. to completely dissolve. In this embodiment, the liniment is in a solution state.
[0183] The sample 13A was microscopically observed under the initial conditions using the method described in Example 3. The results are shown in FIG5 , indicating that there were no crystals in the field of view.
[0184] Comparative Example 1
[0185] Compared with Example 1, the difference is that the prescription is as shown in Table 14 below:
[0186] Table 14
[0187] Comparative Example 2
[0188] Compared with sample 1A of Example 1, the difference is that the active ingredient of the drug is replaced with tofacitinib citrate (batch number: HY-170-35-20200327; purchased from: Shanghai Haoyuan Pharmaceutical Co., Ltd.), and the prepared sample is numbered 2a.
[0189] Comparative Example 3
[0190] The active pharmaceutical ingredient was formulated in 50% PEG400, 10% diethylene glycol monoethyl ether and 40% PEG3350 (50% aqueous solution), and the prepared sample was numbered 3a.
[0191] Effect Example 1 Microscopic Observation Results
[0192] The microscopic results show that, as can be seen from part (a) of Figure 1, part (a) of Figure 4, and Figure 5, the ointment, organogel, and liniment showed no crystallization under the initial conditions. From part (b) of Figure 1, it can be seen that the ointment is stable and has no crystallization for a long time, and the product texture is uniform and the skin feel is good. From part (b) of Figure 4, it can be seen that the organogel has no obvious large-particle crystal precipitation during the stability placement process, and the particle size is no more than 180μm. From Figures 2 and 3, it can be seen that the cream and hydrogel also have no obvious large-particle crystal precipitation under the initial conditions, and the particle size is less than 180μm.
[0193] Effect Example 2 Ointment in vitro release data
[0194] The release amount was calculated using the external standard method. The in vitro release test method is shown in Table 15 below:
[0195] Table 15
[0196] Samples 3A, 3B, 3C and 3D were tested for in vitro release of ointments of different strengths using the above in vitro release assay method. The results are shown in Table 16 below:
[0197] Table 16
[0198] According to Table 16, a trend line is drawn with the square root of time as the abscissa and the amount of drug released per unit area (cumulative) as the ordinate, as shown in Figure 6; the slope of the trend line is the release rate, as shown in Table 17 below:
[0199] Table 17
[0200] With the specification as the horizontal axis and the release rate (slope) as the vertical axis, the curve is drawn as shown in Figure 7. The linear regression and the square of the correlation coefficient (R 2 ) is greater than 0.90, indicating that the release rates of different specifications are linear.
[0201] The results showed that as the content of active pharmaceutical ingredients increased, the release amount and release rate of the ointment increased.
[0202] Effect Example 3 Ointment in vitro percutaneous permeability
[0203] In vitro percutaneous permeation testing of ointments was performed on samples 1C, 1D, 3A, 3B, 3C, 3D, and 1a.
[0204] The test method is as follows:
[0205] Before use, the skin was treated with physiological saline and evenly cut and distributed to each specification of the preparation (6 samples for each specification). A degreased cotton swab was used to apply the active ingredient ointment to the stratum corneum side of the skin. According to the diameter of the diffusion cell, the amount of drug applied was approximately 0.2 g.
[0206] A Franz diffusion cell with a diameter of 2 cm and a receiving fluid of approximately 7 mL was used, using 10% ethanol and saline as the receiving fluid. The treated pig skin was mounted on the Franz diffusion cell with the stratum corneum facing upwards towards the supply cell and the dermis facing downwards towards the receiving cell. 0.2 g of ointment was evenly applied to the stratum corneum. The receiving cell was filled with degassed receiving fluid. The diffusion cell was placed in a constant-temperature water bath at (32 ± 1)°C and stirred continuously with an electromagnetic stirrer at 200 rpm. The receiving fluid was removed from the cell at 2, 4, 6, 8, 10, and 24 hours, and an equal volume of isothermal receiving fluid was added. The receiving fluid to be tested was stored at 5°C. The test was terminated after 24 hours, and the skin in each cup was treated.
[0207] Receiver Solution Preparation: After the in vitro percutaneous permeation test is complete, precisely pipette 200 μL of the receiver solution into a 96-well plate. Add 200 μL of the internal standard solution (50% diclofenac sodium in methanol, 92.76 ng / mL) and vortex for 10 minutes to mix. Centrifuge for 15 minutes (5°C, 4000 g). Precisely pipette 200 μL of the supernatant into another 96-well plate to obtain the test sample.
[0208] Skin Treatment (Remaining Ointment on the Skin Surface): After the in vitro percutaneous permeation test is completed, remove the transdermal diffusion cell and inspect the skin surface for visible ointment. Gently aspirate the liquid from the skin surface with a rubber-tipped dropper to remove as much of the remaining ointment as possible. Transfer the sample to a volumetric flask. Then, use a 1 mL pipette to transfer 2 mL of methanol to the supply cell. Gently scrape the skin surface with a small spoon to dissolve as much of the remaining drug on the skin surface in the methanol. Transfer the wash solution to the same volumetric flask. Repeat this process six times. Ultrasonicate for 15 minutes, then cool and bring to volume with methanol. Store the ointment collection solution at 5°C. Accurately aspirate 10 μL of the ointment collection solution for analysis, dilute with 990 μL of blank matrix, and vortex for 3 minutes to mix thoroughly. Pipette another 200 μL of the above analysis sample into a 1.5 mL EP tube, add 600 μL of internal standard solution (50% diclofenac sodium in methanol, 92.76 ng / mL), and vortex for 10 minutes to mix thoroughly. Centrifuge for 5 min (5°C, 12000 rpm / min); accurately pipette 200 μL of the supernatant into a 96-well plate to obtain the sample to be tested.
[0209] Skin treatment (skin extract): After the ointment on the skin surface is treated, remove the skin, wash off the ointment on the skin surface, and use filter paper to absorb the residual solvent on the skin surface. Use scissors to cut off the outer skin that is not in direct contact with the ointment, leaving only the skin of the same size as the pool opening (about 3.14cm 2), weigh the treated skin, seal it in an EP tube and store it. Cut the skin into pieces, freeze it in liquid nitrogen for more than 1 hour, and then grind it into powder in a freezer grinder. Transfer the grinding balls directly to a 50mL EP tube, transfer the powder to the above-mentioned 50mL EP tube in small amounts and multiple times with 25mL of methanol, sonicate, shake well, and pipette 1mL into a 1.5mL EP tube. The obtained skin extract is sealed and stored at 5°C. Accurately pipette 200μL of skin extract into a 1.5mL EP tube, add 200μL of internal standard solution (50% methanol aqueous solution of diclofenac sodium, 92.76ng / mL), and vortex for 10min to mix. Centrifuge for 5min (5°C, 12000rpm / min); accurately pipette 200μL of supernatant into a 96-well plate to obtain the sample to be tested.
[0210] LC-MS / MS was used to determine the concentrations of the active ingredient in the receiving solution, the remaining ointment on the skin surface, and the skin extract. The cumulative permeation amount and the skin retention amount were calculated.
[0211] The results of the transdermal test are shown in Table 18 below:
[0212] Table 18
[0213] Results Analysis: The in vitro permeation results for samples 1a, 1C, and 1D indicate that as the mass ratios of polyethylene glycol 400 / diethylene glycol monoethyl ether and polyethylene glycol 3350 / diethylene glycol monoethyl ether decrease, the amount retained per unit skin increases. Comparison of the results for samples 3A, 3B, 3C, and 3D indicates that the ointment's skin retention is somewhat correlated with drug loading, with unit skin retention increasing with increasing drug loading. The composition of the present invention exhibits a significantly greater retention / permeation ratio, indicating that the composition enters less bloodstream and presents a lower systemic risk.
[0214] Effect Example 4 Stability Study Results
[0215] Stability studies were performed on samples 3B, 3C, and 3D.
[0216] The analysis method is as follows:
[0217] (1) Shape: The shape of the ointment was checked visually.
[0218] (2) pH value: The ointment was diluted 10 times with purified water that had been freshly boiled and cooled to room temperature. After being shaken to disperse, the pH value was measured using a pH meter.
[0219] (3) Related substances (impurities, types as shown in Table 19 below): Related substances were determined according to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Chapter 0512). The method for determining related substances is as follows: the chromatographic column is a Waters Xselect Hss T3 C18 column (4.6*150mm 3.5μm), with a 10mM ammonium acetate aqueous solution (accurately pipette 0.77g of ammonium acetate into 1000mL of pure water, mix well, and degas) as mobile phase A; acetonitrile as mobile phase B; gradient elution is performed according to Table 20 below; the flow rate is 1.0mL / min; the column temperature is 15℃; the detection wavelength is 254nm; the running time is 45min; the needle washing solution is 50% acetonitrile aqueous solution.
[0220] Table 19
[0221] Table 20
[0222] (3) Content: Determine the content according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition Part IV General Chapter 0512). The content determination method is as follows: use 0.02 mol / L disodium hydrogen phosphate dodecahydrate buffer (weigh 7.20 g disodium hydrogen phosphate dodecahydrate, add 1000 mL of water to dissolve, adjust the pH to 7.80±0.05 with phosphoric acid, and filter with a 0.45 μm water filter membrane to obtain)-acetonitrile (60:40) as the mobile phase, isocratic elution; column temperature is 30 ° C; detection wavelength is 255 nm, flow rate is 1.0 mL per minute, and injection volume is 10 μL. The content detection method is also applicable to the content detection of dibutylhydroxytoluene.
[0223] (4) Viscosity: The viscosity was measured using an American Brookfield viscometer.
[0224] (5) Microscopy: Take a clean glass slide, apply an appropriate amount (about 0.01 g each time) of ointment on the slide, cover it with a cover slip, press the cover slip gently, and observe the ointment under a microscope using an eyepiece of 10X, an objective lens of 40X, and polarized light of 300°.
[0225] Here are the results:
[0226] A. High temperature 50℃, light ≥1.2×10 6 The results of the 30-day stability study under lux·hr conditions are shown in Table 21.
[0227] Table 21 Note: “ND” means below the reporting limit of 0.05% or not detected, and “-” means not applicable.
[0228] B. The results of the 3-month stability study under accelerated conditions (40°C, 75% RH) are shown in Table 22.
[0229] Table 22
[0230] C. The results of a 3-month stability study under long-term conditions (25°C, 60% RH) are shown in Table 23.
[0231] Table 23
[0232] D. During use (32°C, 75% RH), the results of the 2-month stability study are shown in Table 24.
[0233] Table 24
[0234] As shown in Tables 21-24, the pharmaceutical compositions of different strengths showed no significant changes in properties, pH, content, related substances, and viscosity when compared to the results at day 0, after 30 days of exposure to influencing factors, and after 3 months of exposure under accelerated and long-term conditions. Furthermore, the stability during use was also tested, and the results were good. In summary, the pharmaceutical compositions of the present invention exhibit excellent stability when used in pharmaceutical preparations.
[0235] Effect Example 5 Pharmacokinetic (PK) Study Results
[0236] Experimental methods:
[0237] Twenty-four (12 / sex) male and female Bama miniature pigs were divided into five groups. The ointment was applied to an area equivalent to 10% of the animal's estimated body surface area.
[0238] The ointment of sample 2A and sample 2B was applied to the skin once in group 1 and group 2, respectively. Plasma, stratum corneum, epidermis and dermis samples were collected before administration (0, plasma only) and 0.5, 1, 4, 8, 12 and 24 hours after administration.
[0239] The ointment of sample 2B was applied to the skin of the animals in group 3 once a day for 7 consecutive days. Plasma samples were collected before (0) and 0.5, 1, 4, 8, 12, and 24 hours after administration on days 1 and 7, and before (0) on days 3, 4, 5, and 6; stratum corneum, epidermis, and dermis samples were collected 0.5, 1, 4, 8, 12, and 24 hours after administration on day 7.
[0240] The ointment of sample 2a was applied to the skin once to the animals in group 4, and plasma, stratum corneum, epidermis, dermis and subcutaneous tissue samples were collected before administration (0, plasma only) and 0.5, 1, 4, 8, 12 and 24 hours after administration.
[0241] Animals in group 5 received a single skin application of sample 3a (at 6 mg / mL at 25 μL / m 2 Administration), blood and skin samples were collected before (0) and 0.5, 1, 3 and 6 hours after administration. Blood was obtained by venipuncture and collected in tubes containing sodium heparin as an anticoagulant. The exposed skin was washed with soap and water, and then the skin samples were collected. On the administered skin, punch biopsies from the epidermis to the muscle layer were obtained at each time point. The epidermis, dermis, subcutaneous tissue and subcutaneous muscle were quickly separated, weighed and frozen in dry ice. The epidermis and dermis were homogenized in normal saline at a ratio of 1:3 (w / v). The homogenized samples were extracted with three volumes of acetonitrile and quantified using an LC-MS / MS system against a standard curve.
[0242] The concentrations of the active pharmaceutical ingredients in plasma, stratum corneum, epidermis, and dermis were determined by high-performance liquid chromatography-ultraviolet detection (LC-MS / MS).
[0243] Table 25 Note: “h*ng / mL” is the unit corresponding to plasma, and “ng*h / g” is the unit corresponding to skin tissue.
[0244] The results of skin application showed that: comparing the results of 2A and 2B, it was shown that the AUC of different skin layers was positively correlated with the dosage. 0-last The higher the concentration, the more active ingredients of the drug can effectively penetrate the stratum corneum and stay in the effective treatment area. The plasma concentration of all active ingredients of the drug is lower than the lower limit of quantification, which means that the active ingredients of the drug enter the blood less. In addition, 12μg / cm2 of skin application was given once a day for 7 consecutive days. 2 After application of ointment, the exposure in the stratum corneum, epidermis and dermis of males and females (AUC 0-last with C max ) remained basically unchanged, indicating that there was no accumulation of the active ingredient of the drug.
[0245] Compared with the composition of tofacitinib (sample 2a) and the aqueous composition (sample 3a), after application of the composition of the active pharmaceutical ingredient of the present invention, the retention amount of the active pharmaceutical ingredient per unit dose in the epidermis and dermis is much greater than that of sample 2a and sample 3a, indicating that the agent of the present invention can better penetrate the stratum corneum to reach the active site and has better permeability.
[0246] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises a pharmaceutical active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400; the pharmaceutical composition does not contain water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the active pharmaceutical ingredient has the structural formula (I):
2. The pharmaceutical composition according to claim 1, It is characterized in that The dosage of the active pharmaceutical ingredient is 0.001-10%, for example 0.1%, 0.3%, 0.6%, 1.0%, 1.2%, 1.5% or 2.0%, % refers to the mass percentage of the active pharmaceutical ingredient in the pharmaceutical composition; And / or, the amount of diethylene glycol monoethyl ether is 15-40%, for example 20.0%, 23.0% or 33.8%, % refers to the mass percentage of diethylene glycol monoethyl ether in the pharmaceutical composition; And / or, the amount of polyethylene glycol 400 is 30-55%, for example, 30.4%, 38.8%, 45.3%, 52.5% or 52.9%, % refers to the mass percentage of polyethylene glycol 400 in the pharmaceutical composition; and / or, the mass ratio of the pharmaceutically active ingredient to the diethylene glycol monoethyl ether is 1:(10.0-250.0), for example, 1:13.33, 1:15.33, 1:16.67, 1:16.90, 1:20, 1:23, 1:33.33, 1:66.67, 1:76.67, 1:200 or 1:230; And / or, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0), for example, 1:0.90, 1:1.94, 1:1.97, 1:2.63 or 2.65; And / or, the pharmaceutical composition further comprises polyethylene glycol 3350; And / or, the pharmaceutical composition further comprises one or more of an antioxidant, a preservative, a hardener and a humectant.
3. The pharmaceutical composition according to claim 1 or 2, It is characterized in that When the pharmaceutical composition includes polyethylene glycol 3350, the amount of polyethylene glycol 3350 is 25.0-45.0%, such as 25.8%, 26.3%, 26.5%, 27%, 27.2%, 30%, 30.5%, 31.2%, 31.4%, 33.8% or 40%; And / or, when the pharmaceutical composition includes polyethylene glycol 3350, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6), preferably 1:(0.5-3.0), for example 1:1.00, 1:1.29, 1:1.30, 1:1.32, 1:1.33, 1:1.35, 1:1.36, 1:1.37 or 1:2.00; And / or, the antioxidant is an aromatic amine antioxidant, such as butylated hydroxytoluene; And / or, the antioxidant is used in an amount of 0.05-0.2%, such as 0.1%; and / or, the preservative is one or more of methylparaben, sorbic acid and salts thereof, such as methylparaben; and / or, the amount of the preservative is 0.05-0.2%, for example 0.1%; and / or, the hardener is one or more of paraffin, beeswax, cetostearyl alcohol, white vaseline and glyceryl mono- and distearate; and / or, the amount of the hardener is 5-40%, such as 9.8%, 22.1%, 30.65% or 37.6%; and / or, the moisturizing agent is one or more of glycerin, light liquid paraffin, soybean oil, medium chain triglycerides, sodium hyaluronate, urea, propylene glycol, butylene glycol, panthenol, sodium pyrrolidone carboxylate and trehalose, preferably propylene glycol; And / or, the amount of the moisturizer is 2-80%, such as 5.0%, 9.0%, 20.0%, 37.5% or 77.5%.
4. The pharmaceutical composition according to any one of claims 1 to 3, It is characterized in that The pharmaceutical composition comprises the pharmaceutical active ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not include water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6); Preferably, the pharmaceutical composition comprises the pharmaceutical active ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not include water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.0); More preferably, the pharmaceutical composition comprises, by weight percentage:
5. An external preparation, It is characterized in that It comprises the pharmaceutical composition according to any one of claims 1 to 4.
6. The external preparation according to claim 5, It is characterized in that The external preparation is a liquid preparation or a semisolid preparation; The liquid preparation is preferably a liniment or a tincture; the semisolid preparation is preferably a cream, an organogel, an ointment or a paste; Preferably, the ointment comprises, by weight percentage:
7. A method for preparing the pharmaceutical composition according to any one of claims 1 to 6, It is characterized in that It includes the following steps: (1) Preparation of API solution: Mix the active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400 at 50-80°C until dissolved; (2) Prepare the matrix solution: heat polyethylene glycol 3350 at 50-80°C until it melts; (3) Preparation of ointment: Mix the API solution and the base solution under stirring conditions.
8. A method for preparing the pharmaceutical composition according to claim 7, It is characterized in that In step (1), the mixing temperature is 50°C or 80°C; And / or, in step (2), the raw materials further include one or more of an antioxidant, a preservative, a hardener and a humectant; And / or, in step (2), the raw material further comprises diethylene glycol monoethyl ether; preferably, when the raw material in step (2) comprises diethylene glycol monoethyl ether, the amount of diethylene glycol monoethyl ether in step (1) is 2 / 3 of the prescribed amount, and the amount of diethylene glycol monoethyl ether in step (2) is 1 / 3 of the prescribed amount; And / or, in step (2), the heating temperature is 50° C. or 80° C.; And / or, in step (3), the stirring speed is 315 rpm; And / or, in step (3), the stirring time is 10-15 min; And / or, in step (3), the mixing temperature is 50-60°C; And / or, in step (3), after the mixing is completed, a cooling operation is also included.
9. Use of the pharmaceutical composition according to any one of claims 1 to 4, or the external preparation according to claim 5 or 6, in the preparation of a drug for treating autoimmune diseases; Preferably, the autoimmune disease is arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
10. A method for treating an autoimmune disease. It is characterized in that It comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 4, or the external preparation according to claim 5 or 6; Preferably, the autoimmune disease is arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
Citation Information
Patent Citations
Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CN103298794A
JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof
CN106349224A
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN113227074A
Pharmaceutical composition containing pharmaceutically acceptable salt of tofacitinib, preparation and application
CN113975280A
Heterocyclyl pyrimidine analogues as JAK inhibitors
WO2013014162A1
Cited By
Pharmaceutical composition, topical preparation, and preparation method therefor and use thereof
WO2024240229A1
